BR9506507A - Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao - Google Patents

Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao

Info

Publication number
BR9506507A
BR9506507A BR9506507A BR9506507A BR9506507A BR 9506507 A BR9506507 A BR 9506507A BR 9506507 A BR9506507 A BR 9506507A BR 9506507 A BR9506507 A BR 9506507A BR 9506507 A BR9506507 A BR 9506507A
Authority
BR
Brazil
Prior art keywords
nitro
derivatives
microgranules
gastro
pharmaceutical compositions
Prior art date
Application number
BR9506507A
Other languages
English (en)
Portuguese (pt)
Inventor
Gerard Leduc
Patrice Debregeas
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9400394A external-priority patent/FR2715067B1/fr
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of BR9506507A publication Critical patent/BR9506507A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9506507A 1994-01-14 1995-01-12 Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao BR9506507A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9400394A FR2715067B1 (fr) 1994-01-14 1994-01-14 Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal.
PCT/FR1995/000039 WO1995019168A1 (fr) 1994-01-14 1995-01-12 Microgranules de derives de 5-nitro imidazole

Publications (1)

Publication Number Publication Date
BR9506507A true BR9506507A (pt) 1997-09-09

Family

ID=9459066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9506507A BR9506507A (pt) 1994-01-14 1995-01-12 Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao

Country Status (19)

Country Link
JP (1) JPH09507499A (cs)
KR (1) KR100320140B1 (cs)
CN (1) CN1088357C (cs)
AT (1) ATE187068T1 (cs)
AU (1) AU705570B2 (cs)
BR (1) BR9506507A (cs)
CZ (1) CZ286080B6 (cs)
DE (1) DE69513632T2 (cs)
DK (1) DK0739201T3 (cs)
ES (1) ES2139883T3 (cs)
MA (1) MA23429A1 (cs)
MX (1) MX9602772A (cs)
NZ (1) NZ279238A (cs)
OA (1) OA10583A (cs)
PL (1) PL178424B1 (cs)
PT (1) PT739201E (cs)
RU (1) RU2152212C1 (cs)
SK (1) SK282066B6 (cs)
UA (1) UA28031C2 (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
RU2220711C1 (ru) * 2002-04-24 2004-01-10 Закрытое акционерное общество "Брынцалов-А" Противомикробное и противопротозойное средство "трихоброл"
AU2015311674B2 (en) 2014-09-05 2018-03-08 Evofem Biosciences, Inc. Secnidazole for use in the treatment of bacterial vaginosis
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346095A (en) * 1978-02-10 1982-08-24 Mercer James B Therapeutic treatment for viral hepatitis infection
US5256684A (en) * 1985-06-13 1993-10-26 The Procter & Gamble Company Methods and compositions for the treatment of gastrointestinal disorders
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
AU7909691A (en) * 1990-05-14 1991-12-10 Gary R. Jernberg Surgical implant and method incorporating chemotherapeutic agents
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.

Also Published As

Publication number Publication date
SK282066B6 (sk) 2001-10-08
DK0739201T3 (da) 2000-05-01
MX9602772A (es) 1997-05-31
KR100320140B1 (ko) 2002-07-02
AU1580395A (en) 1995-08-01
RU2152212C1 (ru) 2000-07-10
UA28031C2 (uk) 2000-10-16
CZ286080B6 (cs) 2000-01-12
PT739201E (pt) 2000-05-31
CN1088357C (zh) 2002-07-31
CZ205596A3 (en) 1996-10-16
OA10583A (en) 2002-07-10
MA23429A1 (fr) 1995-10-01
PL315530A1 (en) 1996-11-12
SK91496A3 (en) 1996-12-04
AU705570B2 (en) 1999-05-27
ATE187068T1 (de) 1999-12-15
NZ279238A (en) 1998-03-25
DE69513632T2 (de) 2000-04-06
DE69513632D1 (de) 2000-01-05
PL178424B1 (pl) 2000-04-28
CN1138826A (zh) 1996-12-25
JPH09507499A (ja) 1997-07-29
ES2139883T3 (es) 2000-02-16

Similar Documents

Publication Publication Date Title
FR15C0024I2 (fr) Indolinones substituees en position 6, leur preparation et leur utilisation en tant que medicaments
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
TR200002299T2 (tr) Epotilon kompozisyonları.
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
BR1100776A (pt) Forma de dosagem farmacêutica comprimida e obréia farmacêutica comprimida.
HUP0104795A3 (en) Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use
DE60015279D1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
NZ505073A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant, useful for treating allergic, inflammatory and intestinal diseases
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
MXPA03000644A (es) Nuevos derivados de indol y uso como medicamentos.
DK1225902T3 (da) Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden
DE69706146D1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
AU1751997A (en) Targeted delivery of drugs to the lower gastrointestinal tract
PA8449301A1 (es) Composiciones farmaceuticas
BR9506507A (pt) Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao
CA2368767A1 (en) Protease resistant flint analogs
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
TR200102930T2 (tr) Ruhsal bozuklukların tedavisinde yararlı olan ilaçların üretiminde osanetat kullanımı
HUP0200529A3 (en) Optically pure camptothecin analogues, pharmaceutical compositions containing them and their use
WO2001022917A8 (en) Effervescent compositions comprising nimesulide

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 11A, 12A, 13A, 14A, 15A, 16A, 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.